Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 05/06 10:02:31 pm
53.6 USD   -0.91%
05/05DJMARKET SNAPSHOT : S&P 500, Dow End Little Changed Ahead Of Jobs Repo..
05/05DJMARKET SNAPSHOT : U.S. Stocks Try To Avoid 3-day Slide A Day Ahead O..
05/05DJMARKET SNAPSHOT : U.S. Stocks Slump As Investors Adopt Cautious Stan..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:03am CEST
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable.

Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable.

Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said.

A Mylan spokeswoman couldn't immediately be reached.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MERCK & CO., INC.
05/05DJMARKET SNAPSHOT : S&P 500, Dow End Little Changed Ahead Of Jobs Report; Nasdaq L..
05/05DJMARKET SNAPSHOT : U.S. Stocks Try To Avoid 3-day Slide A Day Ahead Of Jobs Repor..
05/05DJMARKET SNAPSHOT : U.S. Stocks Slump As Investors Adopt Cautious Stance
05/05DJMARKET SNAPSHOT : S&P 500, Dow End Little Changed Ahead Of Jobs Report; Nasdaq L..
05/05DJMARKET SNAPSHOT : U.S. Stocks Turn Negative As Oil Futures Pare Gains
05/05 MERCK : Reports Outline Bisphosphonates Findings from Merck & Company (Effects o..
05/05 MERCK : Sanford Heisler Wins Certification Victory in $250 Million Sex Discrimin..
05/05 DOW ANALYST MOVES : Mrk
05/05DJMARKET SNAPSHOT : U.S. Stocks Move Higher, Boosted By Oil's Gains
05/05DJMERCK : Revenue Falls on Generic Competition, Currency -- 2nd Update
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials